MBIO — MindBio Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$6.75m
- CA$8.72m
Annual income statement for MindBio Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | R2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.477 | 7.51 | 3.72 | 0.72 | 2.83 |
| Operating Profit | -0.477 | -7.51 | -3.72 | -0.72 | -2.83 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.477 | -7.51 | -4.29 | -0.411 | -2.81 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.477 | -7.51 | -4.29 | -0.411 | -2.81 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.477 | -7.51 | -4.28 | -0.411 | -2.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.477 | -7.51 | -4.28 | -0.411 | -2.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.43 | -17.7 | -15.6 | -2.2 | -4.84 |
| Dividends per Share |